← Leaderboards
John A Secrist
Southern Research Institute
$6,038,272
Attributed
$6,038,272
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $855.2K · FY2008–12$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$6,038,272 · 7
By mechanism
R01$2,251,169 · 1
P01$1,523,546 · 2
U01$1,087,535 · 1
N01$778,162 · 1
U54$397,860 · 1
U19$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Southern Research Institute
Same institution · by research overlap
- Joseph A Maddry$11,761,444
Others in their field
Top investigators on “Nucleoside Analog”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Robert Turner Schooley · University Of Colorado Denver$49,550,018
- Jeffrey S Glenn · Stanford University$19,514,752
- Ruth Martha Greenblatt · University Of California San Francisco$19,382,210
- Vern L. Schramm · Yeshiva University$18,631,228
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
Research focus
Nucleoside AnalogDrug Design /Synthesis /ProductionStructural BiologyAntineoplasticsCytotoxicityComputer SimulationPurinesNeoplastic CellProdrugsCooperative StudyStructurePharmaceutical PreparationsResearch PersonnelLaboratoriesAnimal ModelEnzymesDna-Directed Dna PolymeraseDesignDrug DiscoveryBaseEvaluationIn VivoCarbohydratesCell Death
Grant awards (20)
4'-Substituted nucleoside analogs as anticancer drugs$441,240
R01 · FY2012 · CA · contact PI
4'-Substituted nucleoside analogs as anticancer drugs$441,240
R01 · FY2011 · CA · contact PI
4'-Substituted nucleoside analogs as anticancer drugs$455,093
R01 · FY2010 · CA · contact PI
4'-Substituted nucleoside analogs as anticancer drugs$456,229
R01 · FY2009 · CA · contact PI
4'-Substituted nucleoside analogs as anticancer drugs$457,367
R01 · FY2008 · CA · contact PI
Drug Design and Synthesis for Orthopoxvirus Infections$397,860
U54 · FY2008 · AI · contact PI
NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS$289,564
U01 · FY2003 · AI
NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS$260,045
U01 · FY2002 · AI
DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES$228,401
P01 · FY2002 · CA
NUCLEOSIDES WITH ALTERED METABOLISM$228,401
P01 · FY2002 · CA
DESIGN /SYNTHESIS OF NUCLEOSIDES ACTIVATED BY E COLI PNP$0
U19 · FY2002 · CA
NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS$272,938
U01 · FY2001 · AI
NUCLEOSIDES WITH ALTERED METABOLISM$228,401
P01 · FY2001 · CA
DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES$228,401
P01 · FY2001 · CA
DESIGN /SYNTHESIS OF NUCLEOSIDES ACTIVATED BY E COLI PNP$0
U19 · FY2001 · CA
TB DRUG SCREENING:TB ANTIMICROBIAL ACQ &COORD. FACILITY$778,162
N01 · FY2000 · AI
DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES$304,971
P01 · FY2000 · CA
NUCLEOSIDES WITH ALTERED METABOLISM$304,971
P01 · FY2000 · CA
NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS$264,988
U01 · FY2000 · AI
DESIGN /SYNTHESIS OF NUCLEOSIDES ACTIVATED BY E COLI PNP$0
U19 · FY2000 · CA